These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20458929)

  • 1. In vitro dissolution profile comparison of an anti-migraine combinational drug in dosage form.
    Hiremath VB; Kaliaperumal K; Bhojraj S; Nanjan MJ
    Se Pu; 2010 Jan; 28(1):93-9. PubMed ID: 20458929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
    Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
    Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.
    Derosier FJ; Lewis D; Hershey AD; Winner PK; Pearlman E; Rothner AD; Linder SL; Goodman DK; Jimenez TB; Granberry WK; Runken MC
    Pediatrics; 2012 Jun; 129(6):e1411-20. PubMed ID: 22585767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneously Improving Mechanical, Formulation, and In Vivo Performance of Naproxen by Co-Crystallization.
    Abbas N; Latif S; Afzal H; Arshad MS; Hussain A; Sadeeqa S; Bukhari NI
    AAPS PharmSciTech; 2018 Oct; 19(7):3249-3257. PubMed ID: 30194682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
    Varum FJ; Merchant HA; Goyanes A; Assi P; Zboranová V; Basit AW
    Int J Pharm; 2014 Jul; 468(1-2):172-7. PubMed ID: 24727141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
    Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
    Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR; Paim CS; Steppe M; Schapoval EE
    J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods.
    Yuksel N; Kanik AE; Baykara T
    Int J Pharm; 2000 Nov; 209(1-2):57-67. PubMed ID: 11084246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.
    Cady R; Nett R; Dexter K; Freitag F; Beach ME; Manley HR
    Headache; 2014 Jan; 54(1):80-93. PubMed ID: 24020994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence.
    Miller DA; Gamba M; Sauer D; Purvis TP; Clemens NT; Williams RO
    Int J Pharm; 2007 Feb; 330(1-2):61-72. PubMed ID: 17034967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparticulate drug delivery system of aceclofenac: development and in vitro studies.
    Shavi GV; Nayak U; Averineni RK; Arumugam K; Meka SR; Nayanabhirama U; Sureshwar P
    Drug Dev Ind Pharm; 2009 Feb; 35(2):252-8. PubMed ID: 18798090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
    Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE
    JAMA; 2007 Apr; 297(13):1443-54. PubMed ID: 17405970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liquisolid formulations on dissolution of naproxen.
    Tiong N; Elkordy AA
    Eur J Pharm Biopharm; 2009 Nov; 73(3):373-84. PubMed ID: 19679184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
    Shibata H; Yoshida H; Izutsu K; Goda Y
    J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles.
    Menegola J; Steppe M; Schapoval EE
    Eur J Pharm Biopharm; 2007 Sep; 67(2):524-30. PubMed ID: 17398084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.
    Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW
    Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.
    Bajerski L; Rossi RC; Dias CL; Bergold AM; Fröehlich PE
    AAPS PharmSciTech; 2010 Jun; 11(2):637-44. PubMed ID: 20373150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.